Emmes Acquires VaxTRIALS

Go back to Newsroom

Emmes Acquires VaxTRIALS

VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth

Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced the acquisition of VaxTRIALS. Headquartered in Panama City, Panama, VaxTRIALS’ 160+ staff members manage and monitor vaccine clinical trial activities throughout Latin America.

Download Go back to Newsroom

Matt Bond Has Joined Emmes as Chief Financial Officer

Go back to Newsroom

Matt Bond Has Joined Emmes as Chief Financial Officer

His M&A Background and Experience with Successful Private-Equity-Backed Companies Will Benefit the Company’s Growth and Diversification Strategy 

Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Matt Bond has become its chief financial officer (CFO). 

Download Go back to Newsroom

Dr. Rama Kondru Named Chief Executive Officer of Veridix AI

Go back to Newsroom

Dr. Rama Kondru Named Chief Executive Officer of Veridix AI

Dr. Kondru Brings a Formidable Blend of Scientific Expertise and Visionary Technology and Data Sciences Leadership Background to Lead the Emmes Group’s New Technology and Artificial Intelligence (AI) Business
    
The Emmes Group today announced that its newly launched Veridix AI business will be led by Dr. Rama Kondru as its’ Chief Executive Officer.

Download Go back to Newsroom

Creation of the Emmes Group Will Advance Company’s 47-year Legacy and Build Clinical Research Infrastructure for the Future

Go back to Newsroom

Creation of the Emmes Group Will Advance Company’s 47-year Legacy and Build Clinical Research Infrastructure for the Future

  • New Business Unit Veridix AI Launched to Embed Technology and AI in Day-to-Day Clinical Operations
  • Dr. Rama Kondru to Join the Emmes Group as CEO, Veridix AI
  • Industry Leader Matthew Holt to Join Board of Directors    

Emmes today announced the creation of the Emmes Group, with Sastry Chilukuri serving as its executive chairman and chief executive officer. The company also announced a new board member, Matthew Holt.

Download Go back to Newsroom

Emmes

The Industry’s First Native Digital and AI Specialty CRO

Advancing human health with scientific rigor and integrity

Welcome to Emmes, a full-service clinical research organization (CRO) dedicated to helping biopharmaceutical, government, non-profit and academic partners achieve their development and human health goals.

Specialties

Emmes’ specialties covers a broad range of therapeutic areas with a particular focus on Vaccines and Infectious Diseases, Ophthalmology, Neuroscience, Cell and Gene Therapy, and Rare Disease.

Capabilities

Emmes Group is a global contract research organization advancing health innovation through a network of specialized brands. With deep roots in public-sector research and a growing presence in the biopharma industry, we integrate scientific rigor, operational excellence, and technology-driven solutions to accelerate the development of safe, effective treatments.

Your Next Steps

Insider Tips for a Successful Application

At Emmes Group, we believe in making the application process as straightforward and supportive as possible. Here’s how to set yourself up for success when applying to join our team:

Subscribe to